Carbohydrate Antigen 19-9 as a Diagnostic Marker for Hepatic Cyst Infection in Autosomal Dominant Polycystic Kidney Disease

American Journal of Kidney Diseases

Volumn 55, Issue 5, 2010, Pages 916-922

  Kanaan, Nada ^a   Goffin, Eric ^a   Pirson, Yves ^a   Devuyst, Olivier ^a   Hassoun, Ziad ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Carbohydrate antigen 19 9 (CA 19 9); cyst fluid; infection; kidney transplant; liver cysts

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CEFTAZIDIME; CIPROFLOXACIN; GAMMA GLUTAMYLTRANSFERASE; MOXIFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAMNESIS; ANTIGEN DETECTION; ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; BLOOD LEVEL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYST FLUID; DIAGNOSTIC VALUE; DRUG RESPONSE; ESCHERICHIA COLI INFECTION; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATOMEGALY; HUMAN; KIDNEY POLYCYSTIC DISEASE; KLEBSIELLA PNEUMONIAE INFECTION; LIVER CYST; LIVER CYST INFECTION; MALE; PERCUTANEOUS DRAINAGE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CYSTS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LIVER DISEASES; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 77249157672     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.12.023     Document Type: Article

References (36)

1. Chauveau D., Fakhouri F., and Grunfeld J.-P. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol. 11 9 (2000) 1767-1775
2. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 369(9569):1287-1301.
3. Telenti A., Torres V.E., Gross Jr. J.B., Van Scoy R.E., Brown M.L., and Hattery R.R. Hepatic cyst infection in autosomal dominant polycystic kidney disease. Mayo Clin Proc. 65 7 (1990) 933-942
4. Migali G., Annet L., Lonneux M., and Devuyst O. Renal cyst infection in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 23 1 (2008) 404-405
5. Bleeker-Rovers C.P., de Sevaux R.G., van Hamersvelt H.W., Corstens F.H., and Oyen W.J. Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 41 6 (2003) E18-E21
6. 18F-fluorodeoxyglucose PET/CT in polycystic kidney disease. Ann Nucl Med. 22 6 (2008) 529-531
7. Tsuji M., Kashihara T., Terada N., and Mori H. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int. 49 4 (1999) 310-317
8. Nakajima T., and Kondo Y. Well-differentiated cholangiocarcinoma: diagnostic significance of morphologic and immunohistochemical parameters. Am J Surg Pathol. 13 7 (1989) 569-573
9. Kitagawa Y., Iwai M., Muramatsu A., et al. Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues. Histopathology 40 5 (2002) 472-479
10. Yanai H., and Tada N. A simple hepatic cyst with elevated serum and cyst fluid CA19-9 levels: a case report. J Med Case Reports 2 (2008) 329
11. Yoshida H., Onda M., Tajiri T., et al. Infected hepatic cyst. Hepatogastroenterology 50 50 (2003) 507-509
12. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 130 6 (1999) 461-470
13. Nishihara S., Narimatsu H., Iwasaki H., et al. Molecular genetic analysis of the human Lewis histo-blood group system. J Biol Chem. 269 46 (1994) 29271-29278
14. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol. 10 suppl 4 (1999) 145-149
15. Atkinson B.F., Ernst C.S., Herlyn M., Steplewski Z., Sears H.F., and Koprowski H. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res. 42 11 (1982) 4820-4823
16. La'ulu S.L., and Roberts W.L. Performance characteristics of five automated CA 19-9 assays. Am J Clin Pathol. 127 3 (2007) 436-440
17. Goonetilleke K.S., and Siriwardena A.K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 33 3 (2007) 266-270
18. Loy T.S., Sharp S.C., Andershock C.J., and Craig S.B. Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases. Am J Clin Pathol. 99 6 (1993) 726-728
19. Mimidis K., Anagnostoulis S., Iakovidis C., and Argyropoulou P. Remarkably elevated serum levels of carbohydrate antigen 19-9 in cystic duct and common bile duct lithiasis. J Gastrointest Liver Dis. 17 1 (2008) 111-112
20. Ong S., Sachdeva A., Garcea G., et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci. 53 12 (2008) 3213-3217
21. Maestranzi S., Przemioslo R., Mitchell H., and Sherwood R.A. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem. 35 pt 1 (1998) 99-103
22. Mann D.V., Edwards R., Ho S., Lau W.Y., and Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 26 5 (2000) 474-479
23. Parra J.L., Kaplan S., and Barkin J.S. Elevated CA 19-9 caused by Hashimoto's thyroiditis: review of the benign causes of increased CA 19-9 level. Dig Dis Sci. 50 4 (2005) 694-695
24. Kodama T., Satoh H., Ishikawa H., and Ohtsuka M. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal. 21 2 (2007) 103-106
25. Del Villano B.C., Brennan S., Brock P., et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 29 3 (1983) 549-552
26. Kim H.-J., Kim M.-H., Myung S.-J., et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol. 94 7 (1999) 1941-1946
27. Iwase K., Takenaka H., Oshima S., et al. Determination of tumor marker levels in cystic fluid of benign liver cysts. Dig Dis Sci. 37 11 (1992) 1648-1654
28. Everson G.T., Taylor M.R.G., and Doctor R.B. Polycystic disease of the liver. Hepatology 40 4 (2004) 774-782
29. Aybek H., Aybek Z., Sinik Z., Demir S., Sancak B., and Tuncay L. Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int J Urol. 13 11 (2006) 1380-1384
30. Meyer A., Kausch I., Krüger S., Fetscher S., Böhle A., and Jocham D. Elevation of CA 19-9 in giant hydronephrosis induced by a renal calculus. Urology 63 2 (2004) 381-382
31. Shudo R., Saito T., Takahashi K., et al. Giant hydronephrosis due to a ureteral stone, and elevated serum levels of CA 19-9. Intern Med. 38 11 (1999) 887-891
32. Suzuki K., Muraishi O., and Tokue A. The correlation of serum carbohydrate antigen 19-9 with benign hydronephrosis. J Urol. 167 1 (2002) 16-20
33. Ohshio G., Ogawa K., Kudo H., et al. Immunohistochemical distribution of CA19-9 in normal and tumor tissues of the kidney. Urol Int. 45 1 (1990) 1-3
34. Akdogan M., Sasmaz N., Kayhan B., Biyikoglu I., Disibeyaz S., and Sahin B. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 87 5 (2001) 337-339
35. Sheen-Chen S.-M., Sun C.-K., Liu Y.-W., Eng H.-L., Ko S.-F., and Kuo C.-H. Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci. 52 11 (2007) 3140-3142
36. Nakamura T., Maruyama K., Kashiwabara H., et al. Diverticulitis causing a high serum level of carbohydrate antigen 19-9: report of a case. Surg Today 32 3 (2002) 282-284